Evidence map›Paper›PMID 40473892›Full record

ReviewPharmaceutical research2025

The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology.

Panos Macheras, Athanasios A Tsekouras, Sergio Sánchez-Herrero, Kosmas Kosmidis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Panos MacherasFaculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. macheras@pharm.uoa.gr.ORCID http://orcid.org/0000-0003-2375-0552
Athanasios A TsekourasPharmaInformatics Unit, ATHENA Research Center, Athens, Greece.
Sergio Sánchez-HerreroDepartment of Computer Science, Multimedia and Telecommunication, Universitat Oberta de Catalunya, Barcelona, Spain.
Kosmas KosmidisDivision of Theoretical Physics, Physics Department, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo show the implications of the incorporation of the Finite Absorption Time (F.A.T.) concept in drug development plans and in generics development and assessment and to examine regulatory implications.

methodsReexamining and reanalyzing published pharmacokinetic data using the pertinent models that are based on F.A.T.

resultsComparing absorption metrics, old and new ones, shows distinct advantages and better accuracy for those based on the F.A.T. CONCEPT:

conclusionThe proposed approaches can be applied successfully in all phases of drug/generics development and guide changes in their strategy and in the relevant regulatory framework.

Indexed as

Drug DevelopmentDrugs, GenericModels, BiologicalPharmacology, ClinicalHumansDrugs, GenericBioequivalenceFinite absorption timeIVIVCOral drugsPharmacokineticsPhysiologically based finite time pharmacokinetic models

Identifiers

PMID40473892
PMCPMC12222261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.